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Statistical indices of cirrhosis morbidity in the population, as well as 
other forms of destructive infl ammatory 
affections of the liver parenchyma, are 
disappointing, considering the growth of 
patients with this pathology [1, 2]. Given 
this, this medical problem is important 
for the entire fi eld of gastroenterology. 
It is clear that the topic chosen for 
the research is also of economic and 
social signifi cance, taking into account 
considerable complications in this group 
of patients [3], rapid development of 
viral hepatic parenchyma affections, 
tumors and other common forms of the 
liver disease in patients of predominantly 
working age [4-6].
When considering the basic concepts 
of schemes chosen for treatment of 
liver cirrhosis and prevention of its 
complications, we proceeded from 
pathogenic substantiation of perspective 
therapeutic and preventive schemes. 
Based on the pathophysiological 
mechanisms of the general infl ammatory 
cell response (meaning hepatocyte, of 
course), we know that any traumatic 
effect on it causes the development of 
a chain of biochemical, morphological 
and other reactions which lead to the 
development of infl ammation with 
some manifestation of the infl ammatory 
stage for some time, meaning the 
alternative component either exudative 
or proliferative one of the infl ammatory 
process [7]. Taking into consideration 
the general pathophysiological 
mechanisms of the typical pathological 
infl ammation process, it is clear that one 
of the pathogeneses of infl ammatory 
and destructive forms of affection of 
the hepatic parenchyma is activation 
of the blood lysosomal enzymes due to 
dysfunction of lysosomal membranes, 
resulting in the powerful and active 
“release” of enzymes from lysosomes 
[8].
Important therapeutic effect in the 
complex treatment of infl ammatory 
affections of the abdominal organs is 
caused by pharmacological compounds 
with anti-infl ammatory properties due to 
their antioxidant, membrane-stimulating, 
energy-effi cient and other effects. One 
of such compounds, which has these 
and anti-infl ammatory properties is 
tivortin (TV) and alpha-lipoic acid 
(ALA), which are also characterised by 
hepatoprotective effects [9, 10].
Objective. Comparative study of 
anti-infl ammatory effi cacy of TV and 
ALA in experimental liver cirrhosis 
(ELC) with a focus on the dynamics of 
the blood proteolysis activity under their 
infl uence.
Materials and methods. The studies 
were conducted under conditions of 
chronic experiment with 180 Wister 
male rats. Work with laboratory animals 
was carried out in compliance with 
fundamental ethical and regulatory 
requirements, and provided by the 
European Commission for Supervision 
of laboratory and other experiments 
involving experimental animals of 
different species.
The model of ELC was reproduced 
in rats, in a toxic liver affection 
with a hepatotropic poison - carbon 
tetrachloride, which caused a direct 
cytolytic effect on the hepatic 
parenchyma [11]. CCl4 solution was 
prepared from the pure (99.99% purity) 
drug by adding the refi ned sunfl ower 
oil (a fi nal solution concentration 
was 50%) and administered orally 
using a plastic probe twice a week 
during 10 weeks. The animals of the 
comparison group (intact rats, n = 9) 
were administered 0.5 ml of 0.9% 
saline solution of NaCl orally in the 
similar conditions. The ELC formation 
was controlled laparoscopically with 
biopsy and subsequent histological 
examination of the biopsy samples 
in animals of both experimental and 
control groups.
When modelling the ELC, 45 of 
171 rats died from acute liver failure 
(mortality rate was 26.3%). 126 rats that 
remained alive were divided into seven 
groups - 18 animals each. They were 
subjected to euthanasia by overdosage 
of aethaminalum-natrium (100 mg/kg, 
intraperitoneally) in 1 hour (group N1), 
in 6 hours (group N2), in 12 hours (group 
N3), in 24 hours (group N4), in 3 days 
(Group N5), in 5 days (group N6) and in 
7 days (group N7) after the development 
of ELC. Blood samples were taken 
from all animals. In blood the activity 
of cathepsin D, cathepsin L, cathepsin 
B, trypsyn-like proteinase (trypsin), 
metalloproteinase carboxypeptidase A 
and carboxypeptidase B were determined 
by the conventional way [12]. But further 
experiments were conducted in two 
sessions: in the fi rst session each group 
had 6 rats, which were examined using 
the markers of the proteolysis activity 
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in the blood in order to determine their 
perspective signifi cance in the dynamics 
of ELC. In the second session each 
group had 12 rats, which were equally 
administered ALA (50mg kg/i.p.) and TV 
(100 mg/kg/i.p.). After this the activity 
of proteolysis markers was determined 
in blood.
The data obtained was statistically 
calculated using the criterion ANOVA, 
which in case of reliability was 
accompanied by Newman-Keuls 
criterion. The minimum expected 
reliability was in p <0.05.
Results and discussion. In the 
dynamics of the ELC development in 
the rat blood in 1 hour of reproduction 
of the pathological condition the acidic 
protease activity – cathepsins of the type 
D, L and B - exceeded the initial data 
by 67%, 75% and 41% (p <0.01; Table. 
1). Hereafter, the investigated enzyme 
activity continued to grow, reaching the 
maximum values in 12 hours of ELC 
modeling (p <0.001). Changes in the 
activity of neutral proteases (trypsin) 
also gained statistical signifi cance, 
starting 1 hour after the ELC induction 
when its activity exceeded the initial 
value by 44% (p <0.01), and fi nishing by 
the 7th day of the pathological process, 
when the trypsin activity was higher 
than the corresponding control indices 
by 56% (p <0.01). In ELC rats without 
treatment, dynamics of the increased 
activity of metalloproteinase was less 
pronounced being 1.5 times higher than 
the corresponding reference data in 6 
hours of the experiment (p <0.05), just 
like carboxypeptidase A and B, which 
were higher than the corresponding 
initial data by 40% (p <0.05) and 73% 
(p <0.001) in 6 hours after inducing the 
pathological condition, and acquired 
maximum activity in 24 hours after the 
ELC induction (Table. 1).
In the second session of studies 
attempts were made to identify the ALA 
therapeutic activity, the introduction of 
which caused a pronounced decrease in 
the activity of proteolytic and lysosomal 
enzymes (Table. 2). Over the course of 6 
hours of ELC, ALA reduced the activity 
of acidic protease of the type D, L and 
B by 34%, 47% and 48%, respectively, 
as compared to such indices in rats with 
ELC without treatment (p <0.01) in 
the same period of time. Such absolute 
numerical values of the acidic protease 
activity were recorded during 5 days 
of the induced pathological condition. 
Approximately in the same way ALA 
affected the activity of trypsyn-like 
proteases, actual fi gures of which, 
according to the modelled conditions, 
were lower starting in 6 hours (by 51% 
less as compared to those before ALA 
introduction) and ending on the 5th day 
of the pathological process (by 36% less 
than without introducing ALA, in both 
cases p <0.01). To the lesser extent ALA 
affected indices of the metalloproteinase 
activity for 12 hours - 5 days (average 
19% - 41%, p <0.05), carboxypeptidase 
A and B - for 12 hours - 5 days (on an 
average 23-41% p <0.05; Table. 2).
Tivortin also brought about the 
normalization effect on the ELC 
course. The data on effectiveness of 
TV concerning normalization of the 
proteolytic lysosomal enzymes during 
the ELC are shown in Table 3. There has 
been approximately the same but less 
when compared to the ALA impact of 
TV on the absolute fi gures, covering the 
activity of the proteolysis system in the 
blood of rats with ELC.
Thus, the course of liver cirrhosis 
is accompanied by activation of acidic, 
trypsyn-like proteases and lysosomal 
enzymes in the rat blood serum, 
indicating the spread of the infl ammatory 
process from hepatocytes to the entire 
body - the generalization of the process. 
Activation of cathepsin D indicates the 
presence of infl ammatory and destructive 
changes in the liver, which refl ects the 
presence of systemic infl ammation under 
the conditions of ELC.
The results obtained suggest that 
activation of the proteolysis system 
in the blood of rats is probably one of 
the pathogenesis links of the disease, 
resulting in amplifi ed intensity of lipid 
peroxidation due to initiation of the 
Table 1.
Dynamics of changes in proteolysis enzyme activity indices in the rat blood with reproduced experimental liver cirrhosis
Studied enzymes Proteolysis enzyme activity in the rat blood in different periods after reproduced ELC 
Initial data 1 hr 6 hr 12 hr 24 hr 3 days 5 days 7 days
Cathepsin D, 
mcmol/mg
0.009±0.001 0.015±
0.001**
0.041±
0.03***
0.048±
0.005***
0.042±
0.004***
0.033±
0.003***
0.016±
0.001***
0.012±
0.01**
Cathepsin L, 
mcmol/mg
0.48±0.04 0.84±
0.08***
2.20±
0.19***
2.75±
0.24***
2.00±
0.17***
1.44±
0.12***
0.80±0.07** 0.62±0.05*
Cathepsin B, 
mcmol/mg
0.062±0.005 0.088±
0.008*
0.276±
0.023***
0.286±
0.026***
0.198±
0.016***
0.144±
0.013***
0.112±
0.009***
0.086±
0.007*
Trypsin-like 
proteinases, mcmol/
mg
0.350±0.027 0.500±
0.044**
1.100±
0.09***
1.600±
0.135***
1.900±
0.174***
1.200±
0.114***
0.900±
0.085***
0.550±
0.035**
Metalloproteinases, 
mcmol/mg
0.06±0.01 0.06±0.01 0.09±0.01* 0.12±0.01** 0.18±
0.01***
0.16±
0.01***
0.10±0.01** 0.07±0.01
Carboxipeptidase А, 
mcmol/mg
70.5±.6.6 82.7±.7.7 118±9
***
200±17
***
176±14
***
134±11
***
108±9
**
74±6
Carboxipeptidase В, 
mcmol/mg
770±67 920±82 1520±144
***
1770±163
***
1671±154
***
1430±132
***
1200±114
**
960±82
Note: * - P<0.05, ** - P<0.01, *** - P<0.001 –reliable discrepancies of the studied indices compared with the corresponding 
initial data (criterion of АNOVА, which was accompanied by a post hoc Student –Newman-Keuls). 
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Table 2.
Infl uence of alpha-lipoic acid on the dynamics of changes in proteolysis enzyme activity indices in the rat blood with 
reproduced ELC
Studied enzymes
Proteolysis enzyme activity in the rat blood in different periods after reproduced ELC
1 hr 6 hr 12 hr 24 hr 3 доби 5 діб 7 діб
Cathepsin D, 
mcmol/mg
0.012±0.001 0.031±0.002** 0.033±0.003** 0.022±0.002** 0.017±0.001** 0.010±0.001** 0.010±0.001
Cathepsin L, 
mcmol/mg
0.56±0.04 1.06±0.09** 1.00±0.09** 0.88±0.08** 0.70±0.07** 0.56±0.05** 0.52±0.04
Cathepsin B, 
mcmol/mg
0.068±0.005 0.106±0.009** 0.110±0.009** 0.108±0.008** 0.094±0.007** 0.080±0.007** 0.072±0.006
Trypsin-like 
proteinases, mcmol/
mg
0.370±0.033 0.550±0.045** 0.750±0.065** 0.800±0.072** 0.700±0.065** 0.550±0.045** 0.400±0.035
Metalloproteinases, 
mcmol/mg
0.06±0.01 0.07±0.01 0.10±0.01** 0.12±0.01** 0.10±0.01* 0.07±0.01* 0.06±0.01
Carboxipeptidase 
А, mcmol/mg
73±6 98±8** 120±10** 109±10** 94±8** 87±7** 72±7
Carboxipeptidase В, 
mcmol/mg
810±7 1000±98* 1100±102** 1170±105** 1030±99* 920±89* 830±76
Note: * - P<0.05, ** - P<0.01 – reliable discrepancies of the indices under study compared with corresponding initial data 
(criterion of АNOVА, which was accompanied by a post hoc Student –Newman-Keuls). 
Table 3.
Impact of tivortin on the dynamics of changes in proteolysis enzyme activity indices in the rat blood with reproduced ELC
Studied enzymes
Proteolysis enzyme activity in the rat blood in different periods after reproduced ELC
1 hr 6 hr 12 hr 24 hr 3 5 діб 7 діб
Cathepsin D, 
mcmol/mg
0.014±0.001 0.037±0.002** 0.036±0.003** 0.028±0.003** 0.022±0.002** 0.012±0.001** 0.010±0.001
Cathepsin L, 
mcmol/mg
0.62±0.05 1.17±0.09** 1.16±0.09** 0.96±0.08** 0.77±0.07** 0.59±0.05* 0.52±0.04
Cathepsin B, 
mcmol/mg
0.071±0.006 0.115±0.009** 0.118±0.009** 0.116±0.009** 0.109±0.009** 0.088±0.008** 0.073±0.006
Trypsin-like 
proteinases, 
mcmol/mg
0.370±0.035 0.590±0.045** 0.820±0.075** 0.970±0.088** 0.810±0.077** 0.670±0.059* 0.440±0.040
Metalloproteinases, 
mcmol/mg
0.06±0.01 0.09±0.01 0.13±0.01 0.18±0.01 0.15±0.01 0.09±0.01 0.06±0.011
Carboxipeptidase А, 
mcmol/mg
75±6 102±9** 126±11** 114±10** 102±9** 91±8** 76±6
Carboxipeptidase В, 
mcmol/mg
820±77 1080±98* 1200±113** 1210±116** 1180±101** 1000±98* 900±83
Note: * - P<0.05, ** - P<0.01 – reliable discrepancies of the indices under study compared with corresponding initial data in 
rats with ELC (criterion of АNOVА, which was accompanied by a post hoc Student –Newman-Keuls).
so-called pathological “vicious circle” 
that strengthens presence of lysosomal 
enzymes in blood, characterized by 
powerful destructive potential. If this 
happens, autocatalytic activation of 
the kinin–kallikrein system will occur. 
It will promote vasodilation, further 
ischemia of the liver parenchyma and the 
rest of the abdominal cavity [7.12]. All 
of the aforesaid fundamentally explains 
the development of the corresponding 
complications in the body in the course 
of development of cirrhosis.
We consider clinical implementation 
of results, explaining the normalization 
effect of ALA and tivortin on the 
proteolytic enzyme system activity 
in ELC, to be useful in future. Their 
hepatoprotective effect (as to inhibition 
of the proteolysis system activity) was 
virtually identical in the manifestation 
with slight advantage in ALA, and 
developed in 6 hours of the ELC course. 
Of interest may be the determined 
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hepatoprotective effects of tivortin, 
the active substance of which is the 
amino acid L-arginine, which is a major 
participant of the ornithine cycle (by 
which the toxic ammonia binds and 
is converted into the non-toxic urea). 
Besides, L-arginine is a substrate for NO 
synthase - a key enzyme of NO synthesis 
in the endothelial cells [13].
Mechanism of action of Tivortin 
is associated with increasing 
concentrations of nitric oxide in the 
body. It activates guanylate cyclase, 
increases the level of cyclic guanidine 
monophsphate in the endothelium of the 
blood vessels, reduces activation and 
adhesion of leukocytes and platelets 
to the endothelium, inhibits protein 
synthesis of adhesion of VCAM-1 
(vascular cell adhesion molecule-1) 
and MCP-1 (monocyte chemoattractant 
protein-1), thereby causing a general 
anti-infl ammatory effect. The drug 
has hepatoprotective properties due 
to antioxidant, membrane stabilizing 
activity and, as a result, there is positive 
impact on energy supply processes in 
hepatocytes. Therefore, this drug may 
be promising as to further study of its 
hepatoprotective effects by modelling.
In our opinion, the data obtained 
is an experimental substantiation of 
expediency of the clinical testing of ALA 
and TV hepatoprotective effects in case 
of their separate application or in terms 
of combined administration in patients 
with cirrhosis. Our results allow us to 
expand the boundaries of experimental 
research in order to determine the 
prospects of clinical or prophylactic 
use of pharmaceutical compounds 
tested in conditions of experimental 
liver cirrhosis, and in similar clinical 
conditions.
Conclusions. 
1. The course of liver cirrhosis in 
the rat blood serum is accompanied 
by activation of the acidic trypsin-
like proteases and lysosomal enzymes 
in the rat blood serum indicating the 
generalization of the infl ammatory 
process.
2. Activation of the proteolysis 
system in the rat blood is probably one 
of the pathogenetic links of proteolysis 
activation in the rat blood, and is 
probably one of the pathogeneses of the 
disease - liver cirrhosis.
3. Normalization of alpha-lipoic 
acid and tivortin impacts on activity of 
the proteolysis system are promising for 
further clinical implementation of the 
results.
4. The data obtained is an 
experimental substantiation of 
expediency of the clinical testing of 
hepatoprotective effects of alpha-
lipoic acid and tivortin in cases of 
individual application or in combined 
administration in patients with liver 
cirrhosis.
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